Identification of therapy-resistant cells driving relapse in Medulloblastoma from integrated spatial transcriptomics and tissue imaging

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2001514

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Medulloblastoma (MB) is the most common cause of cancer related mortality in children, with relapsed MB nearly a universally fatal event. Relapsed MB can be caused by pre-existing rare cells that escape treatment and continue to evolve. This project will identify the organisation of all cell types within patient derived xenograft models of MB, monitoring how this changes throughout tumour progression and drug treatment. We will identify rare cells responsible for driving recurrence.

Funded Activity Details

Start Date: 01-01-2020

End Date: End date not available

Funding Scheme: Ideas Grants

Funding Amount: $749,272.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

bioinformatics | cancer biology | differential gene expression | drug resistance

Related Links